NCT02544061View on ClinicalTrials.gov

NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

February 28, 2018

Conditions
Colostomy Stoma
Interventions
BIOLOGICAL

NM-IL-12

single 12 µg unit subcutaneous (SC) dose of NM-IL-12

DRUG

Placebo

single subcutaneous dose

Trial Locations (3)

21201

University of Maryland, Baltimore

32610

University of Florida, Gainesville

63110-1010

Washington University in St. Louis, St Louis

Sponsors

Lead Sponsor

Neumedicines Inc.
All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

Neumedicines Inc.

INDUSTRY

NCT02544061 - NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds | Biotech Hunter | Biotech Hunter